27
Participants
Start Date
November 30, 2008
Primary Completion Date
March 31, 2012
Study Completion Date
March 31, 2012
Bendamustine
Starting dose of 50 mg/m\^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
UT MD Anderson Cancer Center, Houston
Collaborators (1)
Cephalon
INDUSTRY
M.D. Anderson Cancer Center
OTHER